4,4′-(1E,1′E)-2,2′-(pyrimidine-4,6-diyl)bis(ethene-2,1-diyl)bis(N,N-dimethylaniline) showed a remarkable higher selectivity for aggregated tau, with respect to an early onset diagnosis of AD. This evidence concerns the gene MAPT and Alzheimer disease.